Syngeneic Cell Line Reference Database

Taconic Biosciences' inbred mice and GEMs on defined genetic backgrounds are widely used for syngeneic tumor studies, in which mouse tumor cells are engrafted into hosts from the same genetic background. Use the database of published references below to identify tumor cell lines and associated background strains that are most appropriate for your study.

Filter by:

Cancer Type	Animal Model	Immunogenicity	Metastatic Potential	Cell Line	Citation
Hepatocellular Carcinoma	C3H		++	Hca-F (HCa/16A3-F)	World J. Gastroenterol. 2004 Feb 15;10(4):521-4 Carcinogenesis 2005 Mar;26(3):513-23
Mammary Adenocarcinoma	FVB		+	DB-7(fvb2)	Clin. Exp. Metastasis 2005;22(1):47-59
Melanoma	DBA/2			Cloudman S91 (Clone M-3)	Int. J. Radiat. Oncol. Biol. Phys. 1987 Nov;13(11):1725-33 Prostaglandins 1983 Sep;26(3):449-56 Mol. Ther. 2003 Apr;7(4):498-505 Br. J. Cancer 1988 Jan;57(1):64-9
Lymphoma	Black 6 (B6NTac)			C6VL	J. Immunol. 2004 Jan 15;172(2):929-36 J. Immunol. 1982 Nov;129(5):2293-300
Fibrosarcoma	Black 6 (B6NTac)			MC57G	J. Immunol. 2004 Jan 15;172(2):929-36
Melanoma	Black 6 (B6NTac)	--	++	B16F10	Cancer Res. 1975 Jan;35(1):218-24 Cancer Res. 1999 Aug 15;59(16):4035-41 Nat. Med. 2016 Dec;22(12):1402-1410 Cancer Cell Int. 2013;13:75 Nature 2015 May 07;521(7550):99-104 Life Sci. 2002 Jan 04;70(7):791-8 Mol. Ther. 2003 Apr;7(4):498-505 PLoS ONE 2013;8(6):e66081
Hepatoma	C3H		++	Hepatoma 134 (MH-134)	Cancer Res. 1985 Apr;45(4):1532-5
Lymphosarcoma	C3H			6C3HED	Cancer Res. 1998 Jun 15;58(12):2594-600
Leukemia	Black 6 (B6NTac)	-		RBL-5	J. Immunol. 1976 Oct;117(4):1267-74 J. Natl. Cancer Inst. 1978 Jan;60(1):239-42 J. Natl. Cancer Inst. 1977 Jun;58(6):1661-4
Lung Squamous Cell Carcinoma	DBA/2		+++	KLN205	Cancer Res. 1978 Jul;38(7):2084-90 Cell Rep 2016 May 17;15(7):1505-13 Clin. Cancer Res. 2004 Jan 01;10(1 Pt 1):293-300 In Vitro 1980 Oct;16(10):884-92
Mammary Adenocarcinoma	BALB/c	---		SM1	Proc. Natl. Acad. Sci. U.S.A. 1998 Aug 18;95(17):10067-71 Cancer Res. 1992 Oct 15;52(20):5732-7
Bladder Carcinoma	C3H	+		MBT-2	Urol. Res. 1997;25(3):179-82 Cancer Res. 1977 Aug;37(8 Pt 2):2918-29
Lymphoma	BALB/c			A20 (A-20)	Blood 2009 Nov 12;114(20):4477-85 Adv Hematol 2012;2012:701704 Blood 2010 Jul 15;116(2):226-38 J. Immunol. 1979 Feb;122(2):549-54
Sarcoma	BALB/c	-		Meth A Sarcoma (METH-A)	Cell Prolif. 2001 Aug;34(4):211-22 Cell Prolif. 2003 Apr;36(2):87-100 Mol. Cell. Biol. 1989 Aug;9(8):3385-92 Proc. Natl. Acad. Sci. U.S.A. 1995 Mar 14;92(6):2219-23
Mammary Adenocarcinoma	BALB/c		+++	LM3	Carcinogenesis 2005 Mar;26(3):513-23 Int. J. Oncol. 1997 Sep;11(3):489-96
Lymphoma	Black 6 (B6NTac)			EL-4	Science 1971 Jan 08;171(3966):75-7 J. Immunol. 2004 Jan 15;172(2):929-36 J. Immunol. 2011 Apr 15;186(8):5004-11 Br. J. Cancer 1950 Dec;4(4):372-9
Prostate Adenocarcinoma	Black 6 (B6NTac)			TRAMP-C1D	J. Biol. Chem. 2001 Apr 06;276(14):11204-13 Cancer Res. 1997 Aug 15;57(16):3325-30
Lymphosarcoma	BALB/c			LSTRA	Leuk. Res. 2003 Apr;27(4):351-7 Cancer Res. 1968 Mar;28(3):434-9 EMBO J. 1982;1(12):1579-82 J. Immunol. 1976 Oct;117(4):1267-74 Mol. Cell. Biol. 1984 Dec;4(12):2705-13
Mammary Adenocarcinoma	FVB			H6O5	Oncogene 2012 May 24;31(21):2614-26 Proteomics 2010 Nov;10(21):3800-10
Plasmacytoma	BALB/c			J558	J. Exp. Med. 2001 Nov 05;194(9):1339-48
Lung Carcinoma	Black 6 (B6NTac)		+++	D122 (3LLD122)	Int. J. Cancer 1984 Oct 15;34(4):567-73 Cancer Res. 1999 Aug 15;59(16):4035-41
Ovarian Carcinoma	Black 6 (B6NTac)			MOVCAR 5612	J Ovarian Res 2010 Oct 19;3:24 J. Biol. Chem. 2012 Aug 24;287(35):29873-86
Mammary Adenocarcinoma	BALB/c			D2F2	J. Leukoc. Biol. 1985 Nov;38(5):573-85 Br. J. Cancer 1992 May;65(5):641-8 Cancer Res. 2010 Oct 01;70(19):7431-41 Cancer Gene Ther. 2012 Apr;19(4):282-91
Ovarian Carcinoma	Black 6 (B6NTac)			MOVCAR 5447	J. Biol. Chem. 2012 Aug 24;287(35):29873-86 J Ovarian Res 2010 Oct 19;3:24
Colon Adenocarcinoma	Black 6 (B6NTac)		++	MC-38	Carcinogenesis 2005 Mar;26(3):513-23 Cancer Res. 1975 Sep;35(9):2434-9 Clin. Exp. Immunol. 2009 Jul;157(1):128-38 Nat Commun 2017 Feb 21;8:14572 J. Natl. Cancer Inst. 1976 Apr;56(4):871-3 PLoS ONE 2016;11(9):e0161779 J. Immunother. 2010 Sep;33(7):697-705
Lymphoid Leukemia	DBA/2	+		L1210	J. Immunol. 2006 Jul 01;177(1):162-8 Immunology 2009 Sep;128(1 Suppl):e641-51 J. Natl. Cancer Inst. 1966 Mar;36(3):405-13, 415-21
Fibrosarcoma	DBA/2			SaD2	J. Immunol. 1978 Sep;121(3):1007-9
Mammary Adenocarcinoma	BALB/c			TUBO	J. Immunol. 2000 Nov 01;165(9):5133-42 Mol. Ther. 2013 Jan;21(1):91-100
Sarcoma	129S6	++		F244	Immunology 2013 Jun;139(2):265-74 Cancer Immunol Res 2017 Feb;5(2):106-117 Oncoimmunology 2013 Jun 01;2(6):e24786
Lymphosarcoma	BALB/c			P1798	Mol. Cell. Endocrinol. 1980 Feb;17(2):95-102
Pancreatic Ductal Adenocarcinoma	Black 6 (B6NTac)			6606PDA	Eur Surg Res 2011;47(2):98-107 Cell Biosci 2015;5:51 BMC Cancer 2011 Jan 28;11:40
Reticulum Cell Sarcoma	Black 6 (B6NTac)			M5076 (M5)	Eur. J. Cancer 1996 Oct;32A(11):2011-8 Cancer Res. 1981 Apr;41(4):1271-80
Plasmacytoma	BALB/c		++	J558	Nat Commun 2017 Feb 21;8:14572 J. Natl. Cancer Inst. 1972 Sep;49(3):735-49 Carcinogenesis 2005 Mar;26(3):513-23
Prostate Adenocarcinoma	Black 6 (B6NTac)			TRAMP-C2	Cancer Res. 1997 Aug 15;57(16):3325-30
Mammary Adenocarcinoma	DBA/2	+	+	T1699	Int. J. Cancer 1984 Jan 15;33(1):73-7
Lymphocytic Leukemia	DBA/2			P1534	Int. Arch. Allergy Appl. Immunol. 1969;35(1):20-34
Glioma	Black 6 (B6NTac)	+++		GL261 (Glioma 261)	Cancer Immunol. Immunother. 2015 Apr;64(4):447-57 Cancer Sci. 2006 Jun;97(6):546-53 PLoS ONE 2015;10(3):e0121314
Mammary Adenocarcinoma	BALB/c		++	D2.0R	Carcinogenesis 2005 Mar;26(3):513-23 Clin. Exp. Metastasis 1993 Jan;11(1):103-12
Mammary Adenocarcinoma	C3H			C3HBA	Eur J Cancer 1975 Dec;11(12):891-901
Gastric Adenocarcinoma	Black 6 (B6NTac)			mGC8	BMC Cancer 2006 Mar 14;6:57
Leukemia	C3H	--		DA1-3b	Leuk. Res. 1999 Apr;23(4):415-6 Blood 2004 Oct 01;104(7):2124-33 Gene Ther. 2000 Aug;7(15):1312-6
Lung Carcinoma	Black 6 (B6NTac)		+++	LL/2	Carcinogenesis 2005 Mar;26(3):513-23 Cancer Lett. 1980 Nov;11(1):63-73
Mesothelioma	BALB/c			AB12	Int. J. Cancer 1992 Dec 02;52(6):881-6 Oncol. Rep. 2012 Aug;28(2):707-13 Mol. Ther. 2002 Aug;6(2):210-8
Erythroleukemia	Black 6 (B6NTac)			FBL-3	J. Immunol. 1976 Oct;117(4):1267-74 J. Natl. Cancer Inst. 1978 Jan;60(1):239-42 Cancer Res. 1968 Mar;28(3):434-9
Lymphoma	Black 6 (B6NTac)			E.G7-OVA	Cell 1988 Sep 09;54(6):777-85 J. Immunol. 2011 Apr 15;186(8):5004-11
Lung Carcinoma	BALB/c			ASB-XIV	Cancer Treat Rep 1983 Dec;67(12):1061-5 Cancer Immunol Res 2015 Dec;3(12):1333-43
Hepatoma	C3H	+		Hepatoma 134 (MH-134)	J. Natl. Cancer Inst. 1981 Oct;67(4):947-56 Proc. Natl. Acad. Sci. U.S.A. 2004 Apr 06;101(14):4990-5
Mammary Adenocarcinoma	FVB		+++	Met-1(fvb2)	Clin. Exp. Metastasis 2005;22(1):47-59
Lung Carcinoma	Black 6 (B6NTac)		++	3LL	Cancer Lett. 1980 Nov;11(1):63-73 Blood 2010 Feb 18;115(7):1461-71 Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62 Cancer Res. 1999 Aug 15;59(16):4035-41
Osteosarcoma	BALB/c		+++	K7M2	Carcinogenesis 2005 Mar;26(3):513-23 Clin. Exp. Metastasis 2000;18(3):261-71
Ovarian Carcinoma	Black 6 (B6NTac)			ID8 (MOSEC)	Anticancer Res. 26(4B):2785-9 Carcinogenesis 2000 Apr;21(4):585-91 J. Immunol. 2014 Nov 15;193(10):5327-37 Gynecol. Oncol. 2016 Aug;142(2):332-40 Gynecol. Oncol. 2008 Feb;108(2):385-94
Leukemia	Black 6 (B6NTac)	++		RMA (RBL-5 subclone)	Nature 2015 May 07;521(7550):99-104 J. Immunol. 2014 Feb 15;192(4):1577-86 J. Exp. Med. 1985 Dec 01;162(6):1745-59
Testicular Carcinoma	Black 6 (B6NTac)			M5480	J. Natl. Cancer Inst. 1975 Sep;55(3):623-31
Leukemia	DBA/2			L-5178-Y	J. Immunol. 2009 Feb 15;182(4):1940-53 Mutat. Res. 2017 Feb;814:1-6 Proc. Natl. Acad. Sci. U.S.A. 1996 Jun 25;93(13):6291-6 J. Immunol. 2004 Jul 15;173(2):1012-22
Colon Adenocarcinoma	Black 6 (B6NTac)			MC-38-CEA-1	Cancer Res. 1991 Jul 15;51(14):3657-62
Ovarian Carcinoma	Black 6 (B6NTac)			MOVCAR 5009	J Ovarian Res 2010 Oct 19;3:24 J. Biol. Chem. 2012 Aug 24;287(35):29873-86
Plasmacytoma	C3H			C1.18.4 (C1-18)	Exp. Cell Res. 1970 Apr;60(1):61-77
Gastric Adenocarcinoma	Black 6 (B6NTac)	-		424GC	BMC Cancer 2006 Mar 14;6:57 J Transl Med 2011 Aug 22;9:140
Myeloma	Black 6 (B6NTac)			5T33	Br. J. Cancer 1992 Dec;66(6):1088-93
Bladder Carcinoma	Black 6 (B6NTac)			MB49	J. Immunol. 1997 Jul 01;159(1):351-9
Hepatocellular carcinoma	Black 6 (B6NTac)			Hep-55.1C	Hepatol. Res. 2016 Aug 08; Mol. Carcinog. 1992;6(2):148-58
Mammary Adenocarcinoma	BALB/c		+++	4T1	Breast Cancer Res. 2000;2(5):331-4 Nature 2015 May 07;521(7550):99-104 Carcinogenesis 2005 Mar;26(3):513-23 Clin. Exp. Metastasis 1999 Mar;17(2):163-70 Proc. Natl. Acad. Sci. U.S.A. 2007 Oct 02;104(40):15735-40
Mammary Adenocarcinoma	BALB/c			MC4-L3	Cancer Res. 2001 Jan 01;61(1):293-302
Colon Carcinoma	BALB/c		+++	CT26	Nat Commun 2017 Feb 21;8:14572 Cancer Res. 1980 Jul;40(7):2142-6 Proc. Natl. Acad. Sci. U.S.A. 2005 Jan 11;102(2):419-24 Cancer Res. 2013 Apr 15;73(8):2493-504 PLoS ONE 2016;11(9):e0161779 Carcinogenesis 2005 Mar;26(3):513-23
Prostate Adenocarcinoma	Black 6 (B6NTac)			TRAMP-C1A	Cancer Res. 1997 Aug 15;57(16):3325-30 J. Biol. Chem. 2001 Apr 06;276(14):11204-13
Mammary Adenocarcinoma	Black 6 (B6NTac)		++	E0771	Cell Rep 2014 Mar 27;6(6):992-9 Dis Model Mech 2015 Mar;8(3):237-51 Proc. Soc. Exp. Biol. Med. 1951 Jun;77(2):358-62 Anticancer Res. 25(6B):3905-15 Nat Commun 2016 Jul 13;7:12258
Mammary Adenocarcinoma	BALB/c			MC4-L2	Cancer Res. 2001 Jan 01;61(1):293-302
Mammary Adenocarcinoma	BALB/c		++	D2A1	Carcinogenesis 2005 Mar;26(3):513-23 Clin. Exp. Metastasis 1993 Jan;11(1):103-12
Mammary Adenocarcinoma	BALB/c			MC4-L1	Cancer Res. 2001 Jan 01;61(1):293-302
Mammary Adenocarcinoma	BALB/c		+++	4T07	Int. J. Cancer 1991 Feb 01;47(3):466-72 Carcinogenesis 2005 Mar;26(3):513-23 Cancer Res. 1992 Mar 15;52(6):1399-405 Br. J. Cancer 1987 Nov;56(5):561-9
Squamous Cell Carcinoma	C3H	---		SCC-7	Cancer Lett. 2012 Apr 28;317(2):199-206 Cancer Res. 2016 Aug 15;76(16):4661-72 Br. J. Cancer 1982 Jul;46(1):109-16 Oncol Lett 2013 Dec;6(6):1799-1803
Lung Carcinoma	BALB/c			M109 (Madison Lung)	In Vitro 1977 Apr;13(4):223-31 Cancer Treat Rep 1977 Nov;61(8):1459-70
Gastric Adenocarcinoma	Black 6 (B6NTac)	+		mGC3	BMC Cancer 2006 Mar 14;6:57 J Transl Med 2011 Aug 22;9:140
Mammary Adenocarcinoma	DBA/1			dbrB	Proc. Soc. Exp. Biol. Med. 80(4):696-7
Prostate Adenocarcinoma	Black 6 (B6NTac)	++		TRAMP-C1	Proc. Natl. Acad. Sci. U.S.A. 1997 Jul 22;94(15):8099-103 Cancer Res. 1997 Aug 15;57(16):3325-30
Acute Myeloid Leukemia	Black 6 (B6NTac)			C1498	J. Immunol. 1973 Jun;110(6):1470-5
Hepatocellular Carcinoma	C3H	-		MH134 (MH134-TC)	Cancer Immunol. Immunother. 1987;24(1):8-12 DNA Cell Biol. 2004 Sep;23(9):549-60 Cancer Res. 1985 Apr;45(4):1663-8
Fibrosarcoma	Black 6 (B6NTac)			MCA205	Cancer Immunol Res 2015 May;3(5):526-35 Neoplasia 2015 Aug;17(8):661-70 Oncoimmunology 2013 Jun 01;2(6):e24786
Lymphoma	BALB/c			PU5-1.8 (PU5-1R, TIB-61)	J. Exp. Med. 1976 Jun 01;143(6):1528-33 Cancer Res. 1977 Feb;37(2):546-50
Colon Adenocarcinoma	Black 6 (B6NTac)			MC-38-CEA-2	Clin. Exp. Immunol. 2009 Jul;157(1):128-38 Cancer Res. 1991 Jul 15;51(14):3657-62
Mammary Adenocarcinoma	Black 6 (B6NTac)			Adenocarcinoma 755 (CA755)	Int. J. Radiat. Oncol. Biol. Phys. 4(5-6):395-400 Oncotarget 2013 Oct;4(10):1829-35
Mammary Adenocarcinoma	BALB/c			MC4-L5	Cancer Res. 2001 Jan 01;61(1):293-302
Renal Adenocarcinoma	BALB/c	+	++	RenCa	Cancer Res. 1986 Jul;46(7):3358-63 Carcinogenesis 2005 Mar;26(3):513-23 Mol. Ther. 2003 Apr;7(4):498-505 J. Immunol. 2006 Aug 15;177(4):2575-83
Mast Cell Leukemia	DBA/2	++		P815	J. Immunol. 1984 Jun;132(6):3218-25 Curr Protoc Immunol 2001 May;Chapter 20:Unit 20.4 J. Immunol. 2006 Jul 01;177(1):162-8 Differentiation 1986;32(2):157-64
Pancreatic Adenocarcinoma	Black 6 (B6NTac)		++	Panc02	Clin Transl Sci 2008 Dec;1(3):228-39 Cancer Res. 1984 Feb;44(2):717-26 Eur Surg Res 2011;47(2):98-107 J. Immunother. 2010 Sep;33(7):697-705 J. Immunol. 2010 Oct 01;185(7):4063-71 J Vis Exp 2014 Sep 27;(91):51677 Int J Gastrointest Cancer 2001;29(1):37-46 Curr. Mol. Med. 2012 Mar;12(3):331-41
Leukemia	BALB/c			BCL1	Blood 2012 Jun 28;119(26):6344-53 Biol. Blood Marrow Transplant. 2014 Aug;20(8):1089-103
Colon Carcinoma	BALB/c			MC-26 (Colon 26, C-26)	Cancer Res. 1975 Sep;35(9):2434-9 J. Nutr. 2005 Oct;135(10):2350-4 Proc. Natl. Acad. Sci. U.S.A. 2007 Jul 24;104(30):12457-61 Br. J. Cancer 2002 Aug 27;87(5):574-9
Mammary Adenocarcinoma	C3H	--		CaD2	Proc. Natl. Acad. Sci. U.S.A. 1977 Oct;74(10):4610-4 Cancer Lett. 1992 Jan 31;61(3):263-7
Pleiomorphic Cell Sarcoma	Black 6 (B6NTac)	-		Lewis Sarcoma T241	Anticancer Res. 3(4):263-8 Cancer Res. 2011 Nov 01;71(21):6676-83
Plasmacytoma	C3H	+		X5563	Exp. Cell Res. 1970 Apr;60(1):61-77 Cancer Immunol. Immunother. 1987;24(1):8-12
Osteogenic Sarcoma	C3H			HE 10734	Cancer Chemother Rep 1964 Jan;34:11-7
Lymphocytic Leukemia	DBA/2			P388	Leukemia 1999 Oct;13(10):1592-600
Plasmacytoma	BALB/c			ADJ/PC6	Anticancer Drugs 2005 Jul;16(6):653-7 Immunology 1982 Nov;47(3):503-10
Colorectal carcinoma	BALB/c	-		51BLim10	Cancer Res. 1994 Dec 15;54(24):6477-83
Colon Adenocarcinoma	BALB/c		+++	LM17	Clin. Exp. Metastasis 1999;17(10):849-55
B cell Lymphoma	C3H			38C13	Adv Hematol 2012;2012:701704 Eur. J. Immunol. 1977 Jul;7(7):413-7 Haematologica 2006 Feb;91(2):176-83
Mammary Adenocarcinoma	FVB	-		Tgl-1	Gene Ther. 2006 Oct;13(19):1391-402 Cancer Res. 1998 May 01;58(9):1965-71
Mesothelioma	Black 6 (B6NTac)			AE17	Oncol. Rep. 2012 Aug;28(2):707-13
Mammary Adenocarcinoma	BALB/c		+++	66C14	Breast Cancer Res. 2000;2(5):331-4 J. Cell. Biochem. 1988 Feb;36(2):129-36
Hepatocellular Carcinoma	Black 6 (B6NTac)		-	Dt81Hepa1-6	PLoS ONE 2017;12(2):e0171215
Lymphosarcoma	DBA/2	++	+++	MDW3	Int. J. Cancer 1989 May 15;43(5):828-36 J. Natl. Cancer Inst. 1981 Jan;66(1):129-39 Int. J. Cancer 1984 Nov 15;34(5):709-16
Lymphosarcoma	DBA/2	--	+	MDAY-D2	Blood 2000 Jul 15;96(2):691-8 J. Cell Biol. 1995 Dec;131(6 Pt 2):1849-55 J. Natl. Cancer Inst. 1980 May;64(5):1221-30 Int. J. Cancer 1984 Nov 15;34(5):709-16
Prostate Adenocarcinoma	Black 6 (B6NTac)	-	++	RM-1	Prostate 2009 Nov 01;69(15):1613-23 J. Steroid Biochem. Mol. Biol. 1995 May;52(5):403-13 Nat Commun 2013;4:1795
Prostate Adenocarcinoma	Black 6 (B6NTac)			TRAMP-C3	Cancer Res. 1997 Aug 15;57(16):3325-30
Hepatoma	C3H			Hepatoma 129	Cancer Res. 1987 Dec 01;47(23):6216-9
Melanoma	Black 6 (B6NTac)	--	++	B16	Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62 Cancer Lett. 1984 Aug;24(1):57-63 J. Natl. Cancer Inst. 1970 Oct;45(4):789-800 Carcinogenesis 2005 Mar;26(3):513-23 J. Cell Biol. 1969 Nov;43(2):263-74
Pancreatic Adenocarcinoma	Black 6 (B6NTac)			MT5	Gut 2016 Oct 21;
Squamous Cell Carcinoma	Black 6 (B6NTac)		++	mEERL	J. Virol. 2008 Mar;82(5):2493-500 Oncotarget 2016 Apr 26;7(17):24194-207 Head Neck 2015 Mar;37(3):327-35 Arch. Otolaryngol. Head Neck Surg. 2007 May;133(5):495-502
Lung Adenocarcinoma (transformed with HPV16)	Black 6 (B6NTac)	--	++	TC-1	Nat. Med. 2016 Dec;22(12):1402-1410 Cancer Res. 1996 Jan 01;56(1):21-6 Proc. Natl. Acad. Sci. U.S.A. 2002 Dec 10;99(25):16232-6 Carcinogenesis 2005 Mar;26(3):513-23 Cancer Res. 2013 Apr 15;73(8):2493-504
Plasmacytoma	BALB/c			RPC5.4	Science 1971 Jan 08;171(3966):75-7
Mammary Carcinoma	BALB/c			EMT6	J. Natl. Cancer Inst. 1972 Sep;49(3):735-49

Welcome! Tell us a little about yourself

Syngeneic Cell Line Reference Database

eTACONIC® Platform

Products

Services

Order

Notices & Policies

Resources

Quality

Company